Cost-Effectiveness of Extended and One-Time Screening Versus No Screening for Non-Valvular Atrial Fibrillation in the USA
ConclusionsOur analysis suggests that, screening the general population at age 75 years for NVAF is cost effective at a WTP threshold of $100,000. Both extended screening and one-time screening for NVAF are expected to provide health benefits at an acceptable cost.
Source: Applied Health Economics and Health Policy - Category: Health Management Source Type: research
More News: Atrial Fibrillation | Economics | Electrocardiogram | Epidemiology | Health Management | Heart Attack | Ischemic Stroke | Stroke | Study